{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T11:08:22Z","timestamp":1783940902829,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Enfortumab vedotin plus pembrolizumab (EVP) is the standard first-line treatment for metastatic or locally advanced urothelial carcinoma (m\/laUC). Real-world patients frequently present with unfavorable clinical characteristics, raising uncertainty about whether outcomes mirror those of the pivotal EV-302\/KEYNOTE-A39 trial. This study assessed effectiveness and safety of EVP in a real-world cohort of patients with m\/laUC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Retrospective multicenter study including patients treated with EVP across 25 German hospitals (between 03\/2022 and 08\/2025). Treatment delivery and monitoring followed local clinical standards. Adverse events (AEs) were documented per CTCAE v5.0. Responses were assessed locally using RECIST v1.1. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan\u2013Meier methodology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 468 patients (median age\u2009=\u200969\u00a0years) were included. The overall response rate (ORR) was 50.2% (partial response:37.4%, complete response:12.8%). Median PFS was 10.2\u00a0months (95%CI,8.0\u201312.7). 12-month and 24-month OS rates were 71.9% and 60.6%, respectively. ECOG PS 0\u20131 and occurrence of skin toxicity were associated with improved outcomes. Any-grade AEs occurred in 81.8% and grade\u2009\u2265\u20093 AEs in 35.8%. Peripheral sensory neuropathy and skin toxicity were the most common AEs. Ten treatment-related fatal events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>EVP demonstrated robust effectiveness and manageable toxicity in a large and diverse real-world cohort including patients with divergent histology. Skin toxicity was associated with superior ORR, PFS, and OS. Our findings support EVP as an effective first-line option for patients with m\/laUC treated outside clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-026-04448-2","type":"journal-article","created":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T06:24:02Z","timestamp":1783837442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)"],"prefix":"10.1007","volume":"75","author":[{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozefina","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig Otto","family":"Pachmayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Elegeert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Holzwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severin","family":"Rodler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Rinderknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muammar","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Darr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lisa","family":"Volk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schmucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann","family":"Zengerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Paffenholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joschka","family":"Heil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Erne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhajit","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea Maria","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Foller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"H\u00f6llein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Rhode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Niegisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Katharina","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Heinzelbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Aydogdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Julius","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"issue":"17","key":"4448_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H von der Maase","year":"2000","unstructured":"von der Maase H et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068\u20133077","journal-title":"J Clin Oncol"},{"issue":"17","key":"4448_CR2","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD et al (2011) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy. J Clin Oncol 29(17):2432\u20132438","journal-title":"J Clin Oncol"},{"issue":"10","key":"4448_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1200\/JCO.19.02044","volume":"38","author":"J Rosenberg","year":"2020","unstructured":"Rosenberg J et al (2020) EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 38(10):1041\u20131049","journal-title":"J Clin Oncol"},{"issue":"3","key":"4448_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.0250","volume":"8","author":"S Yajima","year":"2025","unstructured":"Yajima S, Hirose K, Masuda H (2025) Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: a systematic review and meta-analysis. JAMA Netw Open 8(3):e250250","journal-title":"JAMA Netw Open"},{"issue":"10","key":"4448_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"key":"4448_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.536","author":"TB Powles","year":"2025","unstructured":"Powles TB et al (2025) Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302\/KEYNOTE-A39 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.536","journal-title":"Ann Oncol"},{"issue":"8","key":"4448_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105544","volume":"10","author":"MS van der Heijden","year":"2025","unstructured":"van der Heijden MS et al (2025) Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open 10(8):105544","journal-title":"ESMO Open"},{"key":"4448_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/annonc\/annonc1616","author":"TB Powles","year":"2024","unstructured":"Powles TB et al (2024) EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV)\u2009+\u2009pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC). Annals Oncol. https:\/\/doi.org\/10.1016\/annonc\/annonc1616","journal-title":"Annals Oncol"},{"key":"4448_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.745","author":"P Jain","year":"2025","unstructured":"Jain P et al (2025) Clinical efficacy of enfortumab vedotin-pembrolizumab (EV-P) in locally advanced (LA) or metastatic urothelial carcinoma (mUC): a real-world retrospective study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.745","journal-title":"J Clin Oncol"},{"key":"4448_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.5","author":"M Mayer","year":"2025","unstructured":"Mayer M et al (2025) Real-world time on treatment (rwTOT) with first-line (1L) enfortumab vedotin and pembrolizumab (EV+P) after U.S. food and drug administration approval for advanced urothelial cancer (aUC). J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2025.43.5","journal-title":"J Clin Oncol"},{"key":"4448_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.867","author":"T Jindal","year":"2025","unstructured":"Jindal T et al (2025) Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.867","journal-title":"J Clin Oncol"},{"key":"4448_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050739","author":"T Hara","year":"2026","unstructured":"Hara T et al (2026) Real-world safety and early effectiveness of first-line enfortumab vedotin plus pembrolizumab with routine dexamethasone premedication in advanced urothelial carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers18050739","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4448_CR13","doi-asserted-by":"publisher","first-page":"118.e1","DOI":"10.1016\/j.urolonc.2025.10.016","volume":"44","author":"HK Litt","year":"2026","unstructured":"Litt HK, Mamtani R, Chow RD (2026) Outcomes of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer and severe renal dysfunction. Urol Oncol 44(2):118.e1-118.e5","journal-title":"Urol Oncol"},{"issue":"6","key":"4448_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102453","volume":"23","author":"P Jain","year":"2025","unstructured":"Jain P et al (2025) Real-world outcomes of enfortumab vedotin and pembrolizumab in advanced urothelial carcinoma: a multicenter retrospective analysis. Clin Genitourin Cancer 23(6):102453","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"4448_CR15","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/ijc.70203","volume":"158","author":"D Niedersuess-Beke","year":"2026","unstructured":"Niedersuess-Beke D et al (2026) Enfortumab vedotin plus pembrolizumab in treatment-na\u00efve metastatic urothelial carcinoma patients: an Austrian real-world analysis. Int J Cancer 158(6):1654\u20131665","journal-title":"Int J Cancer"},{"key":"4448_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.289","author":"E Kikuchi","year":"2024","unstructured":"Kikuchi E et al (2024) Enfortumab vedotin plus pembrolizumab (EV+P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC): pan-Asian subgroup analysis from EV-302\/KEYNOTE-A39. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.289","journal-title":"Ann Oncol"},{"key":"4448_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115427","volume":"222","author":"S Belka\u00efd","year":"2025","unstructured":"Belka\u00efd S et al (2025) Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. Eur J Cancer 222:115427","journal-title":"Eur J Cancer"},{"key":"4448_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4574","author":"A Arbuiso","year":"2025","unstructured":"Arbuiso A et al (2025) Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4574","journal-title":"J Clin Oncol"},{"issue":"10","key":"4448_CR19","doi-asserted-by":"publisher","first-page":"595.e1","DOI":"10.1016\/j.urolonc.2025.05.016","volume":"43","author":"G Gazzoni","year":"2025","unstructured":"Gazzoni G et al (2025) Enfortumab vedotin-related skin toxicities in patients with urothelial carcinoma: a systematic review and meta-analysis. Urol Oncol 43(10):595.e1-595.e11","journal-title":"Urol Oncol"},{"issue":"6","key":"4448_CR20","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.jaad.2020.11.067","volume":"85","author":"KE Hirotsu","year":"2021","unstructured":"Hirotsu KE et al (2021) Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma. J Am Acad Dermatol 85(6):1610\u20131611","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"4448_CR21","doi-asserted-by":"publisher","first-page":"235237352614379","DOI":"10.1177\/23523735261437911","volume":"12","author":"G Gebrael","year":"2026","unstructured":"Gebrael G et al (2026) Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. Bladder Cancer 12(1):23523735261437910","journal-title":"Bladder Cancer"},{"key":"4448_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf259","author":"A Jang","year":"2025","unstructured":"Jang A et al (2025) Advanced urothelial carcinoma treated with enfortumab vedotin and pembrolizumab: a path to cure? Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf259","journal-title":"Oncologist"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04448-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04448-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:57:25Z","timestamp":1783940245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04448-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4448"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04448-2","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SZ reports fees from advisory bords\/honoraria (institutional and\/or personal) from Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, EUSA, Gilead, Ipsen, Johnson&Johnson, Medac Pharma, Merck, MSD, Novartis, Pfizer, Roche, Sanofi Aventis, StreamedUp, Urotrials, Urotube, Zentiva. Research funding (institutional): Eisai. Clinical trial support (institutional): Amgen, AstraZeneca, AVEO, Bayer, Biontech, Bristol-Myers Squibb, Calithera, Exelixis, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen\/Astellas, Urotrials. Travels & conferences: Amgen, Astellas, AstraZeneca, Bayer, EISAI, Ipsen, Johnson&Johnson, Merck, MSD, Pfizer. JC reports fees from advisory bords\/honoraria (personal) from Johnson&Johnson, MSD, Astellas. Research funding (institutional) from AstraZeneca, MSD. Travels & conferences: Bayer, Johnson&Johnson, Merck, Pfizer. TB reports honoraria from Astellas and Medac Pharma. Travels & conferences: Ipsen, MSD. KS reports fees from advisory bords\/honoraria (personal and\/or institutional) AAA Healthcare, Amgen, Apogepha, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Fosanis, Ipsen, Johnson&Johnson, Merck, MSD, Novartis, Pfizer. Travels & conferences: AstraZeneca, Bayer, Ipsen, Johnson&Johnson, Pfizer. CD reports fees from advisory bords \/honoraria (personal) from Bayer, Ipsen, Johnson&Johnson, MSD. Stock Ownership: Bayer. Research funding (institutional): Deutsche Forschungsgemeinschaft. Travels & conferences: Bayer, Ipsen, Johnson&Johnson, Xeos medical. FZ reports fees from advisory bords\/honoraria (personal) from Amgen, Apogepha, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Ipsen, Johnson&Johnson, Merck, MSD, Novartis, Onkowissen, Pfizer, Roche. Travels & conferences: Astellas, AstraZeneca, Bayer, Ipsen, Johnson&Johnson, Pfizer. PP reports fees from advisory bords\/honoraria (personal) from Apogepha, Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, Ipsen, Johnson&Johnson, Merck, MSD, Novartis, Pfizer, Roche. Travels & conferences: Astellas, AstraZeneca, Ipsen, Johnson&Johnson, Medac Pharma, Merck. EE reports travel & conferences grant from Pfizer. FW reports fees from advisory bords\/honoraria (personal) from Adon Health, Astellas, AstraZeneca, Bayer, Ipsen, Johnson&Johnson, Medac, MSD. SF reports fees from advisory bords\/honoraria (personal) from Bristol-Myers Squibb, Ipsen, Merck, MSD, Novartis, Pfizer, Procept BioRobotics, Roche. AH reports fees from advisory bords\/honoraria (personal) from Abbvie, Gilead Sciences, Johnson&Johnson, Sanofi. Travels & conferences: Abbvie, Johnson&Johnson. AKS reports fees from advisory bords\/honoraria (personal) from Astellas, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, MSD, Roche. MR reports fees from advisory bords\/honoraria (personal) from Astellas, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Lilly, Merck, MSD, Roche. Research funding (institutional): Bristol-Myers Squibb. VG reports fees from advisory bords\/honoraria (personal) from Advanced Accelerator Applications, Amgen, Apogepha, Astellas, AstraZeneca, Bristol-Myers Squibb, Cureteq, Debiopharm Group, Eisai, Gilead Sciences, Ipsen, Johnson&Johnson, Merck, MSD; Novartis, Oncorena, Ono Pharmaceutical, PCI Biotech, Pfizer, Synthekine. Stock ownership: AstraZeneca, Bicycle Therapeutics, Bristol-Myers Squibb, Genmab, MSD. Research funding (Institutional): Amgen, Bicycle Therapeutics, Bristol-Myers Squibb, Gilead Sciences, Ipsen, MSD, Seagen. Travels & conferences: AstraZeneca, Ipsen, Johnson&Johnson, Merck, Pfizer. MJS reports fees from advisory bords\/honoraria (personal) from Apogepha, Astellas, AstraZeneca, Bayer, Gilead Sciences, Ipsen, Johnson&Johnson, Medac, Merck, MSD, Novartis, Pfizer. Stock ownership: BioNtech. Travels & conferences: Ipsen, Johnson&Johnson, Pfizer. The other authors declare no COIs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"184"}}